Incyte Corp at JPMorgan Healthcare Conference Transcript

Jan 08, 2024 / 03:30PM GMT
Jessica Macomber Fye - JPMorgan Chase & Co, Research Division - Analyst

Great. Good morning, everyone. Happy New Year and welcome. I'm Jess Fye, senior biotech analyst at JPMorgan. We're kicking off the Healthcare Conference this morning with Incyte. I'm joined by the company's CEO, Hervé Hoppenot.

And after the presentation, we're going to host a Q&A session. You're welcome to ask questions in the room, you're welcome to submit them over the portal. You're welcome to just listen to me ask questions. But hopefully, you guys will have some of your own as well so we can make it a nice interactive Q&A session after the presentation.

So with that, welcome.

Herve Hoppenot - Incyte Corporation - CEO & Chairman

Very good. Thank you very much. Good morning. So I will speak probably for around 20 minutes. So we're speaking about where we are with Incyte. Before that, forward-looking statement, as usual.

So what I would like to do is to maybe spend a few minutes on where we are today and then give you a picture of where this

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
4.6 out of 5 Trustpilot